Written by: Neal Dave, PharmD and Julianne Orr, PharmD NCODA Spring Forum PQI Workshop
Opioids are commonly utilized in the management of moderate to severe cancer pain. Constipation is a major side effect of opioid administration and should be assessed and managed by the healthcare team.
Continue reading Opioid Induced Constipation (OIC)
Written by: Michelle Hoa and Natasha Heimbigner, PharmD – Summit Cancer Centers
Description of PQI: Patients undergoing cancer treatment are more susceptible to infections due to their compromised immune system. Proactive steps can be taken before cancer therapy to avoid infections. It is important to know which vaccinations patients can or cannot use, when to use them, and to treat them accordingly so they have the proper protection against preventable infections.
Background: Cancer treatments weaken the immune system rendering it more susceptible to infections.1,2 In order to prevent these infections, cancer patients can either take antimicrobial prophylaxis, get vaccinated, or avoid contact with germs.2 Knowing which vaccinations and when to use them are key to avoid patient harm. Generally, it is best to get vaccinated prior to the start of cancer therapy. Live vaccines should be administered at least four weeks prior to the start of chemotherapy and/or at least 3 months after completion of treatment.1,3 Inactive vaccines should be administered 2 weeks prior to the start of therapy for maximal effect; however, they can be given during therapy. Patients vaccinated during chemotherapy treatment with an inactive vaccine should consider revaccination at least 3 months after therapy as they could be rendered ineffective.3
|Type of Immunization||Principle of Action||Examples||Comments|
|Non-replicating vaccines||Based on toxoid, protein subunits, bacterial, antigens, or immunogenic proteins obtained with recombinant, technology.||Tetanus, diphtheria, pertussis, poliomyelitis, hepatitis B, influenza, varicella zoster (shingles) (Shingrix®), Haemophilus influenza, pneumococcus, meningococcus||Usually requires 3–5 doses; antibody titers diminishes with time|
|Replicating live vaccines||Produced by disabling the virulent properties of a disease-producing virus or bacterium||Measles-mumps-rubella, varicella (chicken pox), varicella zoster (shingles) (Zostavax®) intranasal influenza, yellow fever, oral polio, oral typhoid||Severe reactions are possible; transmission of live pathogen may occur; most provide immunity with 1 dose|
|Passive immunization||Antibodies are infused to provide short-term protection||Varicella Immunoglobulin, hepatitis B immunoglobulin||Protection diminishes after weeks or months|
- Obtain patient vaccination history and reference with CDC recommendations to ensure they are current.
- Determine type of vaccination chemotherapy patient needs.
- Non-replicating (inactive) vaccines: should be given at least 2 weeks before the initiation of chemotherapy or other immunosuppressive therapy to maximize immune response.1
- For a healthy immune system, it typically takes up to 2 weeks after vaccination for the immune system to respond to exposed pathogen. Immunocompromised patients may have reduced or no response to vaccine, which may hinder the effectiveness of immunity for patient. Vaccination, 2 weeks prior to chemotherapy, allows immune systems to build an immune response against the targeted pathogen.
- Antibody response is suboptimal if given vaccination during immunosuppressive therapy but is better than not vaccinating.1
- The immune response to vaccine antigens is not as good as that of an immunocompetent patient; repeat vaccination or boosters may be beneficial in prolonging immunity.4
- Replicating live vaccines: should be given at least 4 weeks prior to and at least 3 months after immunosuppressive therapy.1
- Live vaccinations contain a weak live version of the virus it is intended to vaccinate against; however, an immunocompromised system will not be able to fight against it. The live virus could cause vaccine-derived infections
- An adequate immune response usually occurs 3 to 12 months after the completion of chemotherapy. Patients should wait at least 3 months after the completion of therapy to receive live vaccination.5
- Vaccination should be delayed for at least 6 months after treatment if the patient is receiving anti-B-cell antibodies.2
- Based on chemotherapy regimen
- Guide patients to reference the package insert for all oncolytic specific vaccination suggestions
Patient Centered Activities:
- If patient has not been vaccinated, counsel patient on the importance of vaccination.
- Patients who are immunocompromised are at higher risk for certain diseases; additional vaccines are recommended.4
- Immunocompromised patients recommended to receive TIV and polysaccharide-based vaccines (PCV, PPV, MCV4, MPSV, and Hib vaccines).8
- Do get flu vaccination. Do NOT get nasal mist flu vaccine since it is a live vaccine. Live vaccinations are not recommended for immunocompromised patients.
- Influenza-related hospitalization is 3 to 5 times higher in cancer patients.
- Pneumococcal vaccine (PCV13 and PPV23)
- Immunocompromised children and adults should receive PCV13 and are recommended to receive PPV23 vaccine about 8 weeks later.8 Patients then receive a second dose of PPV23 5 years after the first PPV23.8
- Patients that received at least one dose of PPV23 should receive PCV13 no sooner than 1 year after last PPV23 dose.8
- Help patients with weak immune systems fight off serious lung, blood, or brain bacterial infections.7
- Beneficial for patients with multiple myeloma, lung cancer, chronic lymphocytic leukemia, and lymphoma.1
- Zostavax® vs Shingrix®
- Zostavax® is a live attenuated vaccine whereas Shingrix® is an inactivated recombinant zoster vaccine.
- Zostavax® is contraindicated in immunocompromised patients due to it being a live attenuated vaccine.
- While Shingrix® is not contraindicated in immunocompromised persons, it is not recommended by ACIP at this time due to its lack of research.9
- Counsel patients who are on immunotherapy on vaccination recommendations and precautions.
- Immunotherapy has variable immunomodulatory and immunosuppressive effects. Patients undergoing immunotherapy may or may not experience a suppressed immune response.
- Vaccine may be triggering an exaggerated immune response in certain patients.11
- Recent reports suggest that influenza vaccines given to patients on certain types of immunotherapy triggered an amplified immune-related adverse reaction.10,11
- Some patients receiving immune checkpoint inhibitors experienced an intensified immune response.11
- Consult with prescriber if vaccination is appropriate with current immunotherapy.
- Follow up with patient 3 months after chemotherapy is complete.
- If patient had inactive vaccine during chemotherapy, remind patient to get revaccinated 3 months after treatment.
- If patient is over 65 or has an altered immune system, the CDC recommends a flu vaccine every year and pneumonia vaccine (PPSV23) every 5 years. PCV13 vaccine should only be given once.
- Booster Tdap vaccination should be considered for patients who have completed chemotherapy.1 Tdap booster should also be given every 10 years since last Tdap/Td vaccination.
- Counsel family on receiving live vaccines around patients undergoing chemotherapy.
Vaccination Flow Chart:
- Ariza-Heredia, Ella J, and Roy F Chemaly. “Practical Review of Immunizations in Adult Patients with Cancer.” Human Vaccines & Immunotherapeutics 11.11 (2015): 2606–2614.
- Centers for Disease Control and Prevention. Recommendations of the advisory committee on immunization practices (ACIP): Use of vaccines and immune globulins in persons with altered immunocompetence. Morbidity and Mortality Weekly Report. 1993;42(RR-4). Available from: https://dosinghealth.com/wp-content/uploads/2017/09/rr4204.pdf
Written by: Brady Quinn and Britny Rogala, PharmD – University of Rhode Island College of Pharmacy
The utilization of proper diet, over-the-counter medications, and alternative prescriptions can be helpful for patients suffering from multisource drug-induced constipation. Preventing this type of constipation requires less interventions than treating the symptoms once they occur.1
Continue reading Chemotherapy-, Antiemetic-, and Opioid-Induced Constipation
Written by: Kirollos S. Hanna, PharmD, BCPS, BCOP
Patients receiving cancer therapies should be adequately assessed and managed to prevent chemotherapy-induced nausea and vomiting (CINV). 5-hydroxytryptamine (5-HT3) receptor antagonists, neurokinin-1 receptor (NK1R) antagonists, glucocorticoids, benzodiazepines, dopaminergic agents and other therapeutic classes have demonstrated substantial antiemetic activity. Despite proven efficacy, choice of therapy should be tailored to the individual patient based on the distinct types of CINV, patient risk factors and emetogenic potential of therapy. Guidelines for antiemetic therapy for intravenously administered chemotherapy according to the estimated risk of CINV are available from American Society of Clinical Oncology, National Comprehensive Cancer Network and the Multinational Association of Supportive Care in Cancer/ European Society for Medical Oncology1-3. Optimal control and prevention of CINV has been associated with improved adherence to cancer therapy stressing the importance of understanding and adhering to these guidelines4,5.
Continue reading Chemotherapy-Induced Nausea and Vomiting
Written by: Matthew Schulz, RPh Rocky Mountain Cancer Centers
Description:Identify patients who are using Afinitor (everolimus) and could benefit from stomatitis prophylaxis with a steroid mouthwash.
Continue reading Stomatitis